Shomron Ben-Horin (born 1968) (Hebrew: שומרון בן-חורין) is an Israeli physician, a co-founder & Chief Medical Officer of Evinature,[1] and professor of medicine at the Tel-Aviv University.
He received his MD from the Hadassah School of Medicine of the Hebrew University of Jerusalem before completing his gastroenterology training at Sheba Medical Center in Tel Aviv.
[2] He was previously Director of the inflammatory bowel disease service at the Sheba Gastroenterology Department.
After his successful trial on CurQD for patients with ulcerative colitis,[3] Ben-Horin founded Evinature with his research partner, Nir Salomon in 2020.
[5] He has authored over 60 peer-reviewed articles,[6] and served as the principal investigator and sub-investigator in over 20 clinical trials, notably two multi-center prospective randomized controlled trials: Comparison of steroids+5ASA versus steroids alone in acute severe UC (7 sites in Israel, Europe, China and Korea) and one placebo-controlled RCT of Curcumin as add-on therapy for mild-moderate active UC (Israel, Cyprus and Hong-Kong).